Conference Coverage
Video
Education and support enhance care for rare-disease patients
WASHINGTON –
Conference Coverage
When to choose stem cell transplant in PTCL
DUBROVNIK, CROATIA – Dr. Ali Bazarbachi gives his tips for when to use allo- versus auto-HSCT in patients with peripheral T-cell lymphomas.
Conference Coverage
Endocuff decreases withdrawal time but not detection rate during colonoscopy
PHILADELPHIA – Endocuff reduced inspection time to 6.3 minutes, compared with 8.2 minutes in the standard colonoscopy group.
Conference Coverage
Breast cancer in men comparable with women, gonadal therapy debated
MUNICH – Data from a large retrospective study of metastatic breast cancer indicates that, in general, men and women received similar treatments...
Conference Coverage
SOLAR-1 shines light on PI3K in breast cancer
MUNICH – The selective PI3K inhibitor added to fulvestrant extended progression-free survival in breast cancer patients with PIK3CA mutations.
Conference Coverage
Checkpoint inhibitor seems safe and effective for patients with HIV
MUNICH – No immune-related adverse events or deaths due to drug toxicity occurred in cancer patients with HIV treated with nivolumab.
News
Ablation plus transplant for severe scleroderma shows 11-year benefits
CHICAGO – Follow-up to 11 years of patients with severe scleroderma in a stem cell treatment trial documented long-term durability and safety.
Conference Coverage
PCI safely improves iPFS and OS in advanced NSCLC
TORONTO –
Conference Coverage
First-line olaparib doubles PFS in BRCA-mutated advanced ovarian cancer
MUNICH - Olaparib maintenance therapy reduced risk of disease progression or death by 70% compared with placebo in SOLO-1.
Conference Coverage
STAMPEDE: Radiation to prostate boosts survival of metastatic cancer
MUNICH – Patients with low-burden metastatic prostate cancer had an 8% 3-year survival benefit when they received radiation plus androgen...
Conference Coverage
Checkpoint inhibitor/TKI combo improves PFS of RCC over sunitinib
MUNICH – Avelumab and axitinib offered better progression-free survival than did sunitinib as first-line therapy for advanced renal cell carcinoma...